Beijing hospital: ¥4–5 billion in revenue, 20% operating margin, contribution to earnings in the fiscal year ending March 2020
First written in FY2018. 8 of 13 entries say "Advanced", first in FY2019-Q1. Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3AdvancedAnnual report
「In the hospital business in China, approximately 300 outpatients are treated per day, and the 100 inpatient beds and 50 hemodialysis beds are operating at full capacity. An application is currently pending to add inpatient beds.」
In connection with the monetization and expansion targets for the Beijing hospital, the company reported operating levels of approximately 300 outpatient visits per day, 100 inpatient beds, and 50 hemodialysis beds, as well as an application to increase bed capacity. It did not indicate that the existing sales and margin targets had been achieved. - FY2023-Q1RestatedAnnual report
「In the hospital business in China, both the number of visitors and the utilization rate continue to increase, and we are aiming to achieve monthly profitability during fiscal 2022.」
Based on the expected increase in visitor numbers and utilization, the company reconfirmed its existing target of achieving monthly profitability during FY2022. - FY2022-Q3RestatedAnnual report
「In the hospital business in China, the number of visiting patients has steadily increased since treatment covered by public insurance began in February 2021, and we will continue working with our partners to expand the business toward achieving monthly profitability.」
The company reconfirmed its policy of continuing to expand the business toward monthly profitability, based on the increase in patient numbers following the launch of treatment covered by public health insurance. - FY2022-Q1AdvancedAnnual report
「In the China hospital business, the number of visiting patients has gradually increased since treatment covered by public health insurance began in February this year, and we are targeting monthly profitability during the current fiscal year.」
Against the backdrop of increasing patient numbers following the launch of treatment covered by public health insurance, the company presented a specific target of achieving monthly profitability during the current fiscal year. - FY2021AdvancedAnnual report
「We began providing treatment covered by public health insurance in February this year, and the number of patients has been increasing. We believe the business’s future potential will continue to grow as medical needs increase.」
The company reported concrete progress on the monetization and expansion plan for the Beijing hospital, including the launch of treatment covered by public health insurance and an increase in patient numbers. - FY2021-Q3AdvancedAnnual report
「Going forward, we will strengthen the operating structure, increase patient acquisition, and expand the model nationwide across China.」
Regarding the monetization and expansion plan for the China hospital business, the company advanced to the stage of strengthening the operating structure, increasing patient acquisition, and expanding the model nationwide in China following approval for public health insurance coverage. - FY2020SoftenedAnnual report
「At present, partly due to the impact of the COVID-19 pandemic, the increase in the number of patients is slower than expected, but the number of patients is certain to increase once coverage under public insurance begins. Going forward, we will assess the operating status of Hanken Hospital in Beijing and aim to expand the business in China, using the hospital as our flagship.」
Regarding the monetization and expansion plan for the Beijing hospital, the company stated that patient numbers were lagging expectations and that public health insurance coverage was still under application, weakening the wording around progress on the plan. - FY2020-Q2AdvancedAnnual report
「In the hospital operation business in China, we obtained approval to apply for coverage under public insurance earlier than usual and have already completed the application. We are currently preparing to begin treatment covered by public insurance, expand web-based promotion, and broaden the scope of the health management services agreement with our partner, state-owned insurer 中国人民保险集団股份有限公司 (PICC).」
In connection with the monetization plan for the Beijing hospital and its expansion across China, preparations progressed toward increasing patient numbers and earnings, including obtaining approval for and completing the application for public health insurance coverage and expanding the contract with PICC. - FY2020-Q1AdvancedAnnual report
「As the number of patients increases through treatment covered by public health insurance, we expect the shift into more profitable private-pay medical services to accelerate significantly. We are also continuing preparations to open the next 3 hospitals in China.」
At Beijing Hanken Hospital, the company indicated prospects for growth in patient numbers and private-pay medical services starting with treatment covered by public health insurance, while continuing preparations to open the next 3 hospitals in China. - FY2019-Q3RaisedAnnual report
「This business is still in the stage of making upfront investments, but once fully operational, we expect a single hospital to generate sales of approximately ¥4–5 billion and achieve an operating margin of at least 20%. Including future expansion across China, we believe it will become an important contributor to the Group’s earnings.」
While maintaining the expectation of sales of approximately ¥4–5 billion for Beijing Hanken Hospital, the projected operating margin changed from the previous “approximately 20%” to “at least 20%.” The hospital is positioned as an important earnings contributor, including through expansion across China. - FY2019-Q2AdvancedAnnual report
「In the hospital operations business in China, we are steadily progressing toward the full-scale operation of Beijing Hanken Hospital and its contribution to earnings from next fiscal year. We are also continuing preparations to launch the next phase, the opening of 3 hospitals in China.」
The company reported progress toward the full-scale operation of Beijing Hanken Hospital and its contribution to earnings from next fiscal year, while continuing preparations to open the next 3 hospitals in China. - FY2019-Q1AdvancedAnnual report
「Once fully operational, we expect sales of approximately ¥4–5 billion and an operating margin of approximately 20%. As the next phase of development, we have already begun preparing to open 3 hospitals in China.」
The company reconfirmed its expectation of approximately ¥4–5 billion in sales and an operating margin of approximately 20% for Beijing Hanken Hospital, and began preparing to open the next 3 hospitals in China. - FY2018First statedAnnual report
「Once the flagship hospital in Beijing is fully operational, we expect it to generate sales of approximately ¥4–5 billion and achieve an operating margin of approximately 20%. It is expected to begin contributing profit to the Group from the fiscal year ending March 2020.」
The company presented for the first time its business plan for the Beijing flagship hospital, comprising sales of approximately ¥4–5 billion, an operating margin of approximately 20%, and a contribution to Group profit from the fiscal year ending March 2020.